Celltrion Healthcare, 2,591,239 Shares Net Sold by Foreigners in Last 5 Days... Stock Price 106,900 KRW (+0.28%)

As of 2:30 PM on the 14th, Celltrion Healthcare is trading at 106,900 KRW, up 0.28% from the previous day. The trading volume is 1,295,759 shares, which is 117.07% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On July 14, Hana Financial Investment researcher Minjeong Seon stated, "Until the second quarter, Remsima SC was launched only in limited countries (UK, Germany, Netherlands, Ireland) and was approved only for rheumatoid arthritis, which seems to have caused sluggish performance. However, with approval for inflammatory bowel disease expected in the third quarter, it is anticipated to be launched in large markets such as France, Italy, and Spain. Therefore, significant sales of Remsima SC are expected to begin after the third quarter." She set the target price for Celltrion Healthcare at 140,000 KRW.

Over the past five days, individual investors have net purchased 2,289,303 shares of Celltrion Healthcare, while foreigners and institutions have net sold 2,591,239 shares and net purchased 263,701 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.